Palisade Bio Inc (PALI)

$1.80 +0.11 (6.51%)
Market Cap 272.68M
Revenue (ttm) 0.00
Net Income (ttm) -14.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 6,589,000
Avg Vol 10,021,300
Day's Range N/A - N/A
Shares Out 149.00M
Stochastic %K 21%
Beta 1.54
Analysts Strong Sell
Price Target $11.67

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement wi...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4900
Address:
7750 El Camino Real, Suite 2A, Carlsbad, United States
stocksFRlife
stocksFRlife Dec. 4 at 9:34 PM
$PALI Some recovery today, still need to up for green...
0 · Reply
autographic
autographic Dec. 4 at 7:27 PM
$PALI Nice ! 😊
0 · Reply
Machiaveltrade
Machiaveltrade Dec. 3 at 9:54 PM
$PALI add 2 truck 🚛 here
0 · Reply
autographic
autographic Dec. 3 at 8:46 PM
🚨 $PALI has bounced in this zone before -
0 · Reply
Ms_P
Ms_P Dec. 3 at 8:25 PM
$PALI @Kyle7776 Ok, mea culpa you are right! I listened to Marc de Gabriel, it's at 48:13 "study was going nowhere and explanations showed that the person didn't understand what was going on." Wow, harsh!! hhtps://youtu.be/U1k7q1vLZ4M?si=nw-s9HJA1Dd9VE_H
0 · Reply
jerrybe5000
jerrybe5000 Dec. 3 at 8:07 PM
$PALI got out at the open following new info from this chat. Grateful
0 · Reply
TwongStocks
TwongStocks Dec. 2 at 1:51 PM
$PALI Dr. James Izanec appointed as Vice President, Clinical Development https://www.globenewswire.com/news-release/2025/12/02/3197968/0/en/Palisade-Bio-Strengthens-Clinical-Leadership-Team-with-Appointment-of-James-Izanec-MD-AGAF-as-Vice-President-Clinical-Development.html
0 · Reply
Kyle7776
Kyle7776 Dec. 2 at 1:21 PM
$PALI reminder the abvx employee that came to pali was fired from abvx for being incompetent Look it up
2 · Reply
BanditQ
BanditQ Dec. 1 at 7:31 PM
$PALI garbage, nothing to do with $ABVX. If you want abvx comparison buy $EQ !!
0 · Reply
DojiDaddy
DojiDaddy Nov. 28 at 4:03 PM
$PALI
0 · Reply
Latest News on PALI
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Dec 2, 2025, 8:45 AM EST - 2 days ago

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:45 AM EST - 9 days ago

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Oct 28, 2025, 8:45 AM EDT - 5 weeks ago

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Oct 20, 2025, 8:45 AM EDT - 6 weeks ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Oct 13, 2025, 8:45 AM EDT - 7 weeks ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Oct 9, 2025, 5:00 PM EDT - 2 months ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Oct 2, 2025, 4:05 PM EDT - 2 months ago

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Oct 1, 2025, 9:20 AM EDT - 2 months ago

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Sep 26, 2025, 4:05 PM EDT - 2 months ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Sep 17, 2025, 9:00 AM EDT - 2 months ago

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Sep 5, 2025, 8:45 AM EDT - 3 months ago

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 25, 2025, 9:00 AM EDT - 3 months ago

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Aug 7, 2025, 9:15 AM EDT - 4 months ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 31, 2025, 8:45 AM EDT - 4 months ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 23, 2025, 8:00 PM EDT - 4 months ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 4 months ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Jul 9, 2025, 8:45 AM EDT - 5 months ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 27, 2025, 8:30 AM EDT - 6 months ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 6, 2025, 8:30 AM EDT - 7 months ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

May 1, 2025, 8:30 AM EDT - 7 months ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Apr 9, 2025, 8:30 AM EDT - 8 months ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 14, 2025, 8:30 AM EDT - 9 months ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 12, 2025, 8:30 AM EDT - 9 months ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Mar 4, 2025, 8:30 AM EST - 9 months ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 20, 2025, 8:45 AM EST - 10 months ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 10 months ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Feb 10, 2025, 8:45 AM EST - 10 months ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 29, 2025, 8:45 AM EST - 11 months ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 5:20 PM EST - 11 months ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 17, 2024, 8:30 AM EST - 1 year ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 13, 2024, 4:05 PM EST - 1 year ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

What's Going On With Palisade Bio Stock On Thursday?

Dec 12, 2024, 12:55 PM EST - 1 year ago

What's Going On With Palisade Bio Stock On Thursday?

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 12, 2024, 12:05 PM EST - 1 year ago

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Dec 3, 2024, 8:15 AM EST - 1 year ago

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Nov 21, 2024, 8:15 AM EST - 1 year ago

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Nov 12, 2024, 8:45 AM EST - 1 year ago

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Jul 31, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Jul 19, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Jun 21, 2024, 8:15 AM EDT - 1 year ago

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

Jun 11, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

Palisade Bio to Present at the Virtual Investor Pitch Conference

Jun 10, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio to Present at the Virtual Investor Pitch Conference

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

May 21, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

stocksFRlife
stocksFRlife Dec. 4 at 9:34 PM
$PALI Some recovery today, still need to up for green...
0 · Reply
autographic
autographic Dec. 4 at 7:27 PM
$PALI Nice ! 😊
0 · Reply
Machiaveltrade
Machiaveltrade Dec. 3 at 9:54 PM
$PALI add 2 truck 🚛 here
0 · Reply
autographic
autographic Dec. 3 at 8:46 PM
🚨 $PALI has bounced in this zone before -
0 · Reply
Ms_P
Ms_P Dec. 3 at 8:25 PM
$PALI @Kyle7776 Ok, mea culpa you are right! I listened to Marc de Gabriel, it's at 48:13 "study was going nowhere and explanations showed that the person didn't understand what was going on." Wow, harsh!! hhtps://youtu.be/U1k7q1vLZ4M?si=nw-s9HJA1Dd9VE_H
0 · Reply
jerrybe5000
jerrybe5000 Dec. 3 at 8:07 PM
$PALI got out at the open following new info from this chat. Grateful
0 · Reply
TwongStocks
TwongStocks Dec. 2 at 1:51 PM
$PALI Dr. James Izanec appointed as Vice President, Clinical Development https://www.globenewswire.com/news-release/2025/12/02/3197968/0/en/Palisade-Bio-Strengthens-Clinical-Leadership-Team-with-Appointment-of-James-Izanec-MD-AGAF-as-Vice-President-Clinical-Development.html
0 · Reply
Kyle7776
Kyle7776 Dec. 2 at 1:21 PM
$PALI reminder the abvx employee that came to pali was fired from abvx for being incompetent Look it up
2 · Reply
BanditQ
BanditQ Dec. 1 at 7:31 PM
$PALI garbage, nothing to do with $ABVX. If you want abvx comparison buy $EQ !!
0 · Reply
DojiDaddy
DojiDaddy Nov. 28 at 4:03 PM
$PALI
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 28 at 2:50 AM
I’m especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I’ll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.
0 · Reply
jerrybe5000
jerrybe5000 Nov. 26 at 3:36 PM
$PALI sad
2 · Reply
TradeHuntFish
TradeHuntFish Nov. 25 at 11:26 PM
All eyes on DGLY🚨 news , bottomed, tiny float, almost 0 borrow , nearly $10 intrinsic value $BFLY $PALI $POLA $GME
1 · Reply
Set4Gains
Set4Gains Nov. 24 at 2:43 PM
$PALI This.
0 · Reply
S2K_TP
S2K_TP Nov. 21 at 12:48 AM
$PALI on watch 👀
0 · Reply
Stockboi_
Stockboi_ Nov. 20 at 11:40 PM
$PALI sdding here 👀
0 · Reply
ronburgandy75
ronburgandy75 Nov. 20 at 3:10 PM
$PALI the person they hired with a proven track record must have been shown promising data. She would not theow away her successful career unless she understood the potential success. Things may get pretty interesting rather quickly.
1 · Reply
DaBullRunner
DaBullRunner Nov. 20 at 2:50 PM
$PALI there it goes… 🚨SDA🚨🤝 TESLA = $5+ 🎯✅ I’m even willing to put some of my COIN TSLA profits into SDA👇💰💰💰
0 · Reply
DaBullRunner
DaBullRunner Nov. 20 at 12:25 AM
$UMAC you ignored me when I was practically yelling for everyone to get in here in the $4’s with me Now it’s about to hit $10 🚨SDA🚨 adding before it gets crowded here I’m even willing to put some of my COIN TSLA profits into SDA👇💰💰💰 $HODL.X $PALI $CRNC $YMAT let’s get it
1 · Reply
companyofone
companyofone Nov. 19 at 9:59 PM
$PALI waiting on major news, it’s coming. This thing did not do the impossible with that offering then somehow rocket above a $1. They know
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 19 at 8:38 PM
$PALI there is a good reason i split $SNCA in your vault week ish ago swapping snca with BIOC $PSTV
0 · Reply
DARKP00L
DARKP00L Nov. 19 at 3:26 PM
$PALI the market is buzzing about this stock. Expect possible price changes!
0 · Reply